Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 16/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670312 | 0.94 | ENPP2 (0.63) | ENPP2NPC1RAB9AAKR1B1PTGDR2 | |
| SCHEMBL670795 | 0.93 | ENPP2 (0.67) | ENPP2LMNA | |
| SCHEMBL671412 | 0.90 | ENPP2 (0.75) | ENPP2AKR1B1PTGDR2 | |
| SCHEMBL670638 | 0.86 | ENPP2 (0.66) | ENPP2AKR1B1PTGDR2 | |
| SCHEMBL671013 | 0.85 | ENPP2 (0.64) | ENPP2AKR1B1PTGDR2 | |
| SCHEMBL671766 | 0.85 | ENPP2 (0.67) | ENPP2AKR1B1PTGDR2 | |
| SCHEMBL671699 | 0.85 | ENPP2 (0.62) | ENPP2AKR1B1PTGDR2 | |
| SCHEMBL19389436 | 0.84 | ENPP2 (0.57) | ENPP2AKR1B1PTGDR2 | |
| SCHEMBL670280 | 0.84 | ENPP2 (0.77) | ENPP2AKR1B1PTGDR2 | |
| SCHEMBL671619 | 0.84 | ENPP2 (0.65) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9849109-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9849109-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9849109-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-2606031-B1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2606031-B1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20150164861-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150164861-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150164861-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-9000025-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000025-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000025-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2606031-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | Amira Pharmaceuticals, Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012024620-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024620-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885NPC1 2339/4885LMNA 1423/4885 |
| US-20150164861-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885NPC1 2339/4885LMNA 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.